Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ASCO GU 2025: EV-302: Updated Analysis from the Phase 3 Global Study of ...
ESMO 2023: EV-302/KEYNOTE-A39: Enfortumab Vedotin in Combination with ...
ASCO GU 2024: Enfortumab Vedotin in Combination with Pembrolizumab ...
EV-302 Updates at ASCO 2025: Enfortumab Vedotin Plus Pembrolizumab ...
ESMO 2023: Discussant: EV-302/KEYNOTE-A39 & CheckMate 901: Welcoming a ...
ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus ...
ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in ...
ASCO GU 2024: Advanced Urothelial Carcinoma Discussant
EV-302 Trial Confirms Sustained Survival Benefits with Padcev-Keytruda ...
EAU 2024: State-of-the-Art Lecture: New Standard Treatment for ...
Nowy standard leczenia raka urotelialnego: przełomowe wyniki badania EV ...
EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups ...
EV-302 data on EV/pembro in urothelial carcinoma published in NEJM ...
Frontiers | Enfortumab vedotin plus pembrolizumab as a first-line ...
Frontiers | Enfortumab vedotin in metastatic urothelial carcinoma: the ...
Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial ...
Cost-effectiveness Analysis in the New Era of Treatment Strategies in ...
Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer
New drug combination redefines first-line treatment for advanced ...
ESMO 2024: EV-302: Exploratory Analysis of Nectin-4 Expression and ...
Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A ...
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma ...
ASCO GU 2022: Study EV-302: A Two-Arm, Open-Label, Randomized ...
Optimizing Treatment Strategies for Advanced Urothelial Cancer: What ...
NARUS 2024: A Glimpse Into the Future of Robotic Urology | GU Oncology Now
ASCO 2025: EV-302: Long-Term Subgroup Analysis from the Phase 3 Global ...
Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting ...
ESMO 2021: Analysis of Hard-to-Treat Subgroups from EV-301, a Phase 3 ...
A plain language summary of the EV-302/KEYNOTE-A39 study: evaluating ...
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer
ESMO 2025: Enfortumab Vedotin + Pembrolizumab in Previously Untreated ...
EV-302: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in ...
ESMO 2023: Biomarkers of Treatment - Related Toxicity in Advanced ...
EV-302: advancing treatment for metastatic urothelial carcinoma ...
Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV ...
EV-302: Long-term subgroup analysis from the phase 3 global study of ...
EV-302: Updated Analysis From the Phase 3 Global Study | GU Oncology Now
Pfizer and Astellas Highlight EV-302 Trial Results at ASCO GU 2025 ...
Exploratory subgroup analyses of EV-302: a phase III global study to ...
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or ...
Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ...
ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of ...
ASCO 2024: PROs from a Randomized, Phase 3 Trial of Enfortumab Vedotin ...
EV-302: The Trial That Revolutionized First-Line Bladder Cancer ...
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients ...
SUO 2025: Simulating Outcomes of EV-302 with Use of Maintenance ...
Subgroup Analyses and Progression After EV-302 | GU Oncology Now
Implications of EV 302: How Do We Sequence Drug Therapies in Bladder ...
Frontiers | Managing potential adverse events during treatment with ...
.jpg?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
